东诚药业: 关于分拆子公司上市的一般风险提示性公告

Group 1 - The company has approved a proposal for the spin-off of its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., to be listed on the main board of the Hong Kong Stock Exchange [1] - The decision was made during the 13th meeting of the 6th Board of Directors held in Yantai, Shandong Province [1] - The company emphasizes the accuracy and completeness of the information disclosed, ensuring no false records or misleading statements [1] Group 2 - There are risks associated with the spin-off, including the potential for the process to be suspended or terminated due to an investigation for insider trading [1] - The approval process for the spin-off involves multiple steps, including internal decision-making, regulatory filings with the China Securities Regulatory Commission, and reviews by the Hong Kong Stock Exchange [1]